Patients should also contact their provider promptly if they experience: Persistent or worsening nausea and vomiting lasting more than a few days Inability to maintain adequate oral intake of food or fluids Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat), particularly if taking tirzepatide with insulin or sulfonylureas Signs of allergic reaction, including rash, itching, swelling, or difficulty breathing Changes in vision or symptoms of diabetic retinopathy progression, especially with rapid improvement in blood glucose New lump or swelling in the neck, hoarseness, or difficulty swallowing (potential thyroid tumor symptoms) Routine follow-up should address less urgent concerns such as persistent mild nausea affecting quality of life, ongoing constipation or diarrhea, injection site reactions that don't resolve, or questions about dose adjustment
An improved classification of stationary phases for ultra-high performance supercritical fluid chromatography
Semaglutide is a glucagon-like peptide (GLP-1) receptor agonist (RA) that continues to find wider use
Frequently Asked Questions Is oral semaglutide as effective as the injection for weight loss
Wegovy 1.0 mg Cost: 187.00 By weeks 9 to 12, Wegovy treatment may progress to a 1.0 mg weekly dose, providing stronger appetite regulation and continued support for weight-management goals
PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: a network meta-analysis
